Patents by Inventor Bernt Borretzen
Bernt Borretzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6762175Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.Type: GrantFiled: April 5, 2002Date of Patent: July 13, 2004Assignee: Norsk Hydro ASAInventors: Finn Myhren, Bernt Børretzen, Are Dalen, Marit Liland Sandvold
-
Publication number: 20040063677Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.Type: ApplicationFiled: September 16, 2003Publication date: April 1, 2004Applicant: Norsk Hydro ASAInventors: Finn Myhren, Bernt Borretzen, Are Dalen, Marit Liland Sandvold
-
Publication number: 20030153544Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH 2 O—, RCH 2 NH—, —COOCH 2 R, —CONHCH 2 R and —SCH 2 R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.Type: ApplicationFiled: April 5, 2002Publication date: August 14, 2003Inventors: Finn Myhren, Bernt Borretzen, Are Dalen, Marit Liland Sandvold
-
Patent number: 6548486Abstract: New compounds of the general formula (I): Nu-O-Fa, wherein O represents an oxygen, Nu is a nucleoside or nucleoside analogue, and Fa is an acyl group of a mono-unsaturated C18 or 20 fatty acid. The invention also concerns anti viral pharmaceutical and veterinary compositions comprising a compound of formula (I) alone in a combination with a pharmaceutically acceptable carrier.Type: GrantFiled: September 21, 1994Date of Patent: April 15, 2003Assignee: Norsk Hydro a.s.Inventors: Are Dalen, Finn Myhren, Bernt Børretzen, Kjell Torgeir Stokke
-
Patent number: 6384019Abstract: The invention provides Gemcitabine esters or amides in which the 3′- and/or 5′-OH group and/or the N4-amino group is derivatised with a C18- and/or C20-saturated or mono-unsaturated acyl group, preferably an acyl group selected from oleoyl, elaidoyl, cis-eicosenoyl and trans-eicosenoyl. The Gemcitabine esters and amides are useful as anti-cancer and anti-viral agents.Type: GrantFiled: September 15, 1999Date of Patent: May 7, 2002Assignee: Norsk Hydro ASAInventors: Finn Myhren, Bernt Børretzen, Are Dalen, Marit Liland Sandvold
-
Publication number: 20020042391Abstract: The invention provides Gemcitabine esters or amides in which the 3′- and/or 5′-OH group and/or the N4-amino group is derivatised with a C18- and/or C20-saturated or mono-unsaturated acyl group, preferably an acyl group selected from oleoyl, elaidoyl, cis-eicosenioyl and trans-eicosenoyl. The Gemcitabine esters and amides are useful as anti-cancer and anti-viral agents.Type: ApplicationFiled: September 15, 1999Publication date: April 11, 2002Inventors: FINN MYHREN, BERNT BORRETZEN, ARE DALEN, MARIT LILAND SANDVOLD
-
Patent number: 6335322Abstract: wherein R is selected from the group consisting of elaidoyl, cis-eicosenoyl and trans-eicosenoyl; and pharmaceutical compositions comprising the Ara-C derivative.Type: GrantFiled: November 9, 1999Date of Patent: January 1, 2002Assignee: Norsk Hydro ASAInventors: Finn Myhren, Bernt Børretzen, Are Dalen, Kjell Torgeir Stokke
-
Patent number: 6316425Abstract: This invention relates to new nucleoside derivatives of formula (I); wherein R1 and R2 are independently selected from hydrogen, elaidoyl, oleoyl, stearoyl, eicosenoyl (cis or trans) and eicosanoyl, with the provisos that R1 and R2 cannot both be hydrogen, oleoyl or stearoyl, R1 cannot be hydrogen when R2 is oleoyl or stearoyl, and R2 cannot be hydrogen when R1 is elaidoyl, oleoyl or stearoyl. Further, the invention relates to the use of the nucleoside derivatives of formula (I) wherein R1 and R2 are independently selected from hydrogen, and C18- and C20-saturated and mono-unsaturated acyl groups, with the provisos that R1 and R2 cannot both be hydrogen, in the manufacture of a pharmaceutical preparation for the treatment of tumours.Type: GrantFiled: May 26, 1998Date of Patent: November 13, 2001Assignee: Norsk Hydro ASAInventors: Finn Myhren, Bernt Børretzen, Are Dalen, Kjell Torgeir Stokke
-
Publication number: 20010006962Abstract: The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO—, RCONH—, RCOS—, RCH2O—, RCH2NH—, —COOCH2R, —CONHCH2R and —SCH2R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.Type: ApplicationFiled: September 27, 1999Publication date: July 5, 2001Inventors: FINN MYHREN, BERNT BORRETZEN, ARE DALEN, MARIT LILAND SANDVOLD
-
Patent number: 5502077Abstract: Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.Type: GrantFiled: June 23, 1992Date of Patent: March 26, 1996Assignee: Norsk Hydro A.S.Inventors: Harald Breivik, Bernt Borretzen, Knut H. Dahl, Hans E. Krokan, Kaare H. Bonaa
-
Patent number: 5393741Abstract: New compounds having the general formula I ##STR1## wherein Y may be H or D; and A is H, D, alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms or OR wherein R is H or alkyl of 1-4 C-atoms;X.sub.1 and X.sub.2 may together with the carbon atom to which they are bound form a cyclic acetal, thioacetal, dithiane, aminal, oxazolidine or thiazolidine;or pharmaceutically acceptable salts thereof.The compounds are useful as anti-carcinoma agents.Type: GrantFiled: November 27, 1991Date of Patent: February 28, 1995Assignee: Norsk Hydro a.s.Inventors: Erik O. Pettersen, Rolf O. Larsen, Bernt Borretzen, John M. Dornish, Reidar Oftebro
-
Patent number: 5324859Abstract: New compounds of formula I: ##STR1## wherein Y may be CN or ##STR2## wherein A may be H, D, alkyl with 1-4 carbon atoms, OR wherein R is H or alkyl with 1-4 carbon atoms, or --NR.sub.1 R.sub.2 or --CR.sub.1 R.sub.2 R.sub.3 wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and are H or alkyl with 1-4 carbon atoms;Z is H, D, Y or alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms, or --OR wherein R may be H or alkyl with 1-4 C-atoms or --CR.sub.4, R.sub.5 R.sub.6 wherein R.sub.4, R.sub.5 and R.sub.6 may be the same or different and may be H or F;and pharmaceutically acceptable salts thereof,are useful as anti-cancer agents or as intermediates for preparing anti-cancer agents.Type: GrantFiled: January 19, 1993Date of Patent: June 28, 1994Assignee: Norsk Hydro A.S.Inventors: Erik O. Pettersen, Rolf O. Larsen, John M. Dornish, Bernt Borretzen, Reidar Oftebro, Thomas Ramdahl
-
Patent number: 5149820Abstract: Deuterated aromatic aldehydes of the formula: ##STR1## where Ar is substituted phenyl, and derivatives thereof represented by the formula: ##STR2## where Ar is substituted or unsubstituted phenyl, and X.sub.1 and X.sub.2 are substituted hetero atoms or together with the carbon to which they are attached form a heterocycle. These compounds are useful as anticancer and analgesic agents.Type: GrantFiled: August 21, 1989Date of Patent: September 22, 1992Assignee: Norsk Hydro A.S.Inventors: Bernt Borretzen, Rolf O. Larsen, Erik O. Pettersen, John M. Dornish, Reider Oftebro
-
Patent number: 5135948Abstract: The use of L-ascorbic acid, or a pharmaceutically acceptable salt thereof, in combination with 5,6-O-benzylidene-L-ascorbic acid, or 5,6-O-benzylidene-L-ascorbic acid deuterated at least at the 1-position of the aldehyde group of the benzylidene moiety, or a pharmaceutically acceptable salt of such acids, results in a synergistically enhanced cytotoxicity on human carcinoma cells.Type: GrantFiled: September 12, 1990Date of Patent: August 4, 1992Assignee: Norsk Hydro a.s.Inventors: Bernt Borretzen, Rolf O. Larsen, John M. Dornish, Reidar Oftebro, Erik O. Pettersen
-
Patent number: 5130145Abstract: Anti-cancer platinum complexes such as cisplatin exhibit a synergistically higher level of anti-tumour activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.Type: GrantFiled: June 20, 1991Date of Patent: July 14, 1992Assignee: Norsk Hydro A.S.Inventors: Reidar Oftebro, Erik O. Pettersen, John M. Dornish, Bernt Borretzen, Rolf O. Larsen
-
Patent number: 5049396Abstract: Anti-cancer platinum complexes such as cisplatin exhibit a synergistically high level of anti-tumor activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.Type: GrantFiled: March 27, 1989Date of Patent: September 17, 1991Assignee: Norsk Hydro A.S.Inventors: Reidar Oftebro, Erik O. Pettersen, John M. Dornish, Bernt Borretzen, Rolf O. Larsen
-
Patent number: 5032610Abstract: The use of L-ascorbic acid, or a pharmaceutically acceptable salt thereof, in combination with 5,6-O-benzylidene-L-ascorbic acid, or 5,6-O-benzylidene-L-ascorbic acid deuterated at least at the 1-position of the aldehyde group of the benzylidene moiety, or a pharmaceutically acceptable salt of such acids, results in a synergistically enhanced cytotoxicity on human carcinoma cells.Type: GrantFiled: November 21, 1988Date of Patent: July 16, 1991Assignee: Norsk Hydro ASInventors: Bernt Borretzen, Rolf O. Larsen, John M. Dornish, Reidar Oftebro, Erick O. Pettersen
-
Patent number: 4874780Abstract: Deuterated aromatic aldehydes of the formula: ##STR1## where Ar is substituted phenyl, and derivatives thereof represented by the formula: ##STR2## where Ar is substituted or unsubstituted phenyl, and X.sub.1 and X.sub.2 are substituted hetero atoms or together with the carbon to which they are attached from a heterocycle. These compounds are useful as anticancer agents.Type: GrantFiled: March 11, 1987Date of Patent: October 17, 1989Assignee: Norsk Hydro a.s.Inventors: Bernt Borretzen, Rolf O. Larsen, Erik O. Pettersen, John M. Dornish, Rolf Oftebro